Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ATRA

ATRA - Atara Biotherapeutics Inc Stock Price, Fair Value and News

$5.52-0.04 (-0.72%)
Market Closed

85/100

ATRA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

85/100

ATRA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$7.83

Target 3M

$6.52

Target 6M

$7.05

ATRA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ATRA Price Action

Last 7 days

20%

Last 30 days

-69.3%

Last 90 days

-60.7%

Trailing 12 Months

-34.0%

ATRA RSI Chart

ATRA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ATRA Valuation

Market Cap

39.8M

Price/Earnings (Trailing)

1.7

Price/Sales (Trailing)

0.29

EV/EBITDA

1.12

Price/Free Cashflow

-0.57

ATRA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$7.83

Target 3M

$6.52

Target 6M

$7.05

ATRA Fundamentals

ATRA Revenue

Revenue (TTM)

128.9M

ATRA Earnings

Earnings (TTM)

23.4M

Earnings Growth (Yr)

80.36%

Earnings Growth (Qtr)

-280.27%

ATRA Profitability

EBT Margin

18.16%

Return on Equity

313.94%

Return on Assets

77.57%

Free Cashflow Yield

-175.38%

ATRA Investor Care

Shares Dilution (1Y)

25.18%

Diluted EPS (TTM)

3.47

ATRA Alerts

  • 1 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
202434.7M66.1M97.5M128.9M
202349.8M36.1M22.3M8.6M
202224.1M71.8M70.9M63.6M
20214.2M8.0M13.2M20.3M
2015272.0K412.0K762.0K0
201440.3K68.5K96.8K125.0K
201300012.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Atara Biotherapeutics Inc

ATRA
Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.
 CEO
 WEBSITEatarabio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES317

Atara Biotherapeutics Inc Frequently Asked Questions

ATRA is the stock ticker symbol of Atara Biotherapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Atara Biotherapeutics Inc is 39.8 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ATRA's fair value in chart for subscribers.

The fair value guage provides a quick view whether ATRA is over valued or under valued. Whether Atara Biotherapeutics Inc is cheap or expensive depends on the assumptions which impact Atara Biotherapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ATRA.

As of Wed Jan 28 2026, ATRA's PE ratio (Price to Earnings) is 1.7 and Price to Sales (PS) ratio is 0.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ATRA PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Atara Biotherapeutics Inc has provided -0.356 (multiply by 100 for percentage) rate of return.